Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials...
Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials...
EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with...
AUDUBON, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced...
Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over...
Awarded $15 Million Procurement Contract from Canadian Department of National Defence for Oral TPOXX in October Corporate Update Conference Call Today...
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026Expanding potential opportunity...
TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech...
Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX...
Concludes 30-Year Tenure Leading Development of TPOXX®, the First FDA-Approved Antiviral for the Treatment of SmallpoxNEW YORK, Nov. 09, 2026...
NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused...
Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in GBS...
Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) --...
Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLCPresented encouraging Phase 1 data for ARR-217, a CDH17-targeted...
Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 Plans to Initiate...
Physicians at Novant Health Orthopedics & Sports Medicine Institute explain when hip replacement may be appropriate, what recovery involves and...
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
PALO ALTO, CA / ACCESS Newswire / November 10, 2026 / Bioz, Inc., a scientific intelligence platform that converts publication...
DentScribe 2.165.0 passed 68 of 68 tests with 1,967 of 1,967 expected entries correct and zero extra entries in the...
National analysis highlights top-performing skilled nursing facilities in clinical outcomes, safety and resident care.SummaryMore than 14,600 skilled nursing facilities evaluated...
MyoGlow Reviews And Complaints: Researching My Derma Dream's 4-In-1 Arm Device, Real Benefits, Safety, And Refund Policy (Consumer Research) MIAMI,...